Photo Credit: Scyther5
During AAD 2025, psoriasis will be a key area of focus. Leading up to the event, which is occurring in Orlando, Florida, March 7-11, 2025, Dr. Alan D Kaye, Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, published recent data on psoriasis. Below is a review of his research.
In a recent publication in Cureus, researchers conducted a narrative review to provide information regarding the evolving treatment landscape for psoriasis, which affects an estimated 3% of adults in the United States, and the number of cases continues to rise.
Dr. Kaye, Anesthesiology, and colleagues wrote, “Although biologic therapies targeting interleukin (IL)-17 and IL-23 have significantly improved the treatment landscape for moderate-to-severe psoriasis, they are not effective for all patients. This highlights the need for additional therapeutic strategies.”
Dr. Kaye and colleagues noted that treating psoriasis remains challenging, and emerging therapies provide clinicians and patients with hope for more efficacious and patient-centered targeted therapies.
Novel therapies under investigation include interleukin (IL-21), small nucleolar RNA (snoRNA) Snora73, the gut microbiome, and natural remedies that have demonstrated clinical benefits in managing psoriasis. For example, interleukin-21 is a cytokine that has a significant role in the differentiation and function of Th17 cells, which have a key role in the etiology of psoriasis.
Moreover, recent studies have demonstrated that neutralizing IL-21 with specific antibodies has the potential to aid in the restoration of immune homeostasis, decrease the severity of psoriasis, and enhance overall clinical outcomes.
Dr. Kaye and colleagues wrote, “Targeting IL-21 may be particularly beneficial for patients resistant to conventional therapies like IL-17 and IL-23 inhibitors. In addition to IL-21, snoRNA Snora73 has emerged as a novel target for psoriasis treatment. Snora73 regulates cell proliferation by interacting with miR-3074-5p and pre-B-cell leukemia homeobox 1 (PBX1), promoting abnormal cell turnover in psoriasis.”
The narrative review also highlighted the correlation between imbalances in the gut microbiome and the increased risk of developing autoimmune diseases, including psoriasis. Research reveals that gut microbiome imbalance is associated with the exacerbation of autoimmune diseases, including psoriasis, prompting or worsening systemic inflammation, and modifying or compromising a patient’s immune responses.
Moreover, research shows that natural treatments such as luteolin, piperine, quercetin, and curcumin are associated with anti-inflammatory properties and could be employed with traditional therapies as adjunctive therapies due to their anti-inflammatory, antioxidant, and immunomodulatory properties.
The authors wrote, “ These natural therapies could serve as adjuncts to existing treatments, offering a complementary approach that minimizes side effects while improving patient outcomes.”
Dr. Kaye and colleagues concluded, “Integrating novel therapies into clinical practice could redefine the standard of care for psoriasis. With continued innovation and collaboration across disciplines, psoriasis management could become more effective, comprehensive, and tailored to individual patient needs. By addressing the limitations of current therapies and embracing these new strategies, clinicians and researchers can provide renewed hope for patients living with the burdensome condition of psoriasis.”
Finally, the authors concluded that ongoing research might provide insight into novel, more effective, patient-centered treatment of psoriasis, and focusing on emerging therapies such as IL-21, Snora73, and the gut microbiome and utilizing natural therapies is promising.
